Peptide therapeutics that meet the challenges of modern medicine
Endevica Bio was formed in 2009 to create best-in-class peptide drug candidates with better safety and efficacy properties, and its technology platform enables peptide modifications for improved half-life, oral activity, and blood-brain barrier crossing.